Sermorelin

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the naturally occurring 44-amino acid growth hormone-releasing hormone (GHRH). These 29 amino acids represent the bioactive portion of GHRH, meaning Sermorelin retains the full biological activity of the native hormone. It was developed in the 1980s and received FDA approval in 1997 under the brand name Geref for diagnostic evaluation and treatment of growth hormone deficiency in children.

As a GHRH analog, Sermorelin works by binding to GHRH receptors on the pituitary gland, stimulating the natural production and release of growth hormone. This mechanism is fundamentally different from exogenous growth hormone administration because it preserves the body's natural feedback loops. The pituitary gland still regulates GH output through normal feedback mechanisms, which theoretically reduces the risk of excessive GH levels and associated side effects.

Although the branded product Geref was discontinued by the manufacturer (EMD Serono) in 2008 for commercial reasons rather than safety concerns, Sermorelin has continued to be available through compounding pharmacies. It has become a cornerstone of anti-aging medicine and hormone optimization practices, where it is prescribed off-label for adults with age-related declines in growth hormone. Many clinicians prefer Sermorelin over direct GH replacement because of its physiological mechanism and favorable safety profile.

Clinical studies have shown that Sermorelin can increase GH secretion, improve body composition, enhance sleep quality, and support overall vitality. Research in older adults demonstrated improvements in lean body mass, skin thickness, and general well-being. The peptide is often considered a good entry point for those exploring GH optimization, as it is one of the most extensively studied GHRH analogs with decades of clinical use data.